TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A POPULATION-BASED DIRECT-TO-SMOKER OUTREACH OFFERING TOBACCO TREATMENT IN A HEALTH CARE SETTING: A RANDOMIZED CONTROLLED TRIAL
Brief Summary: Tobacco use is the leading preventable cause of death in the United States. Effective treatment for tobacco dependence exists and includes counseling and pharmacotherapy with nicotine replacement, bupropion, or varenicline. The health care system is a key channel for delivering this treatment to smokers. Brief clinical interventions delivered at office visits increase smoking cessation rates, are among the most cost-effective of medical interventions, and are recommended by U.S. Public Health Service. However, physicians and other clinicians often fail to provide them. Clinicians' rates of providing tobacco treatment in ambulatory care can be improved, but even when successful, clinicians can only reach smokers who make an office visit.

A health care system might improve its delivery of tobacco treatment by supplementing visit-based efforts with a population-based strategy, using methods proven effective in public health settings. A population of smokers could be identified from electronic health records and offered treatment proactively in a way that maximizes convenience and minimizes barriers such the cost of pharmacotherapy. This study tests the effectiveness of a population-based Direct-to-Smoker (DTS) outreach program provided to smokers in one community health center in Revere, MA, that is part of an integrated health care system. It uses the system's population management tools to identify smokers and proactively offers them evidence-based tobacco treatment that is free and does require making an office visit. A randomized controlled trial will compare the effectiveness of the DTS program to usual primary care. The hypothesis is that adding the DTS program to usual primary care will increase the proportion of smokers who use tobacco dependence treatment and thereby stop smoking.


Options:
A: Intervention Type: DRUG; Name: bupropion SR (sustained-release); Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Early hospital discharge facilitated by close nurse practitioner follow-up; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Pharmacist intervention; Assigned to Arm(s): N/A
D: Arm Label: Usual clinical care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DTS intervention; Type: EXPERIMENTAL; Interventions: Other: Direct to Smoker Outreach Program | Intervention Type: OTHER; Name: Direct to Smoker Outreach Program; Assigned to Arm(s): DTS intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control
Brief Summary: The purpose of this study is to assess whether glycemic control (assessed with HbA1c measurement) in individuals with type 1 or type 2 diabetes can be improved with a point-of-care measurement of HbA1c in the ophthalmologist's office combined with a personalized risk assessment for diabetic retinopathy and other complications of diabetes.


Options:
A: Arm Label: Diabetes Educational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Education | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diabetes Education; Assigned to Arm(s): Diabetes Educational Intervention
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Peer counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Assigned a peer counselor | Arm Label: Financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentives | Intervention Type: BEHAVIORAL; Name: Assigned a peer counselor; Assigned to Arm(s): Peer counseling | Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): Financial incentives
C: Arm Label: Feedback report only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Goal-Setting Worksheet; Type: EXPERIMENTAL; Interventions: Other: Worksheet to facilitate goal-setting and action plans | Intervention Type: OTHER; Name: Worksheet to facilitate goal-setting and action plans; Assigned to Arm(s): Goal-Setting Worksheet
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: Accu-Chek Aviva Meter | Arm Label: B; Type: EXPERIMENTAL; Interventions: Device: Accu-Chek Aviva Meter | Intervention Type: DEVICE; Name: Accu-Chek Aviva Meter; Assigned to Arm(s): A | Intervention Type: DEVICE; Name: Accu-Chek Aviva Meter; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.


Options:
A: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A
B: Arm Label: NVA237; Type: EXPERIMENTAL; Interventions: Drug: NVA237, Drug: Placebo to tiotropium, Drug: salbutamol/albuterol | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Placebo to NVA237 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo to tiotropium; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo to NVA237; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: salbutamol/albuterol; Assigned to Arm(s): NVA237
C: Arm Label: Fluticasone Furoate / GW642444 (vilanterol); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg | Arm Label: Fluticasone Propionate / salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg; Assigned to Arm(s): Fluticasone Furoate / GW642444 (vilanterol) | Intervention Type: DRUG; Name: Fluticasone Propionate 250mcg/ salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate / salmeterol
D: Arm Label: Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol | Arm Label: Vilanterol 25 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol; Assigned to Arm(s): Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol 25 Inhalation Powder

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (PoliorixTM) in Healthy Chinese Toddlers
Brief Summary: This study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in the primary study. The study will also assess the immunogenicity and reactogenicity of a booster dose of IPV in subjects primed with three doses of IPV.


Options:
A: Arm Label: Poliorix Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral Poliovirus vaccine | Intervention Type: BIOLOGICAL; Name: Poliorix™; Assigned to Arm(s): Poliorix Group | Intervention Type: BIOLOGICAL; Name: Oral Poliovirus vaccine; Assigned to Arm(s): Control Group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Inactivated types 1, 2, and 3 poliovirus, D antigens | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Inactivated types 1, 2, and 3 poliovirus, D antigens; Assigned to Arm(s): Group B
C: Intervention Type: BIOLOGICAL; Name: Inactivated Polio Vaccine given at an accelerated schedule; Assigned to Arm(s): N/A
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM, Biological: Infanrix+Hib | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Infanrix+Hib | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Infanrix+Hib; Assigned to Arm(s): Group A, Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of a Booster Dose of GlaxoSmithKline Biologicals' IPV (PoliorixTM) in Healthy Chinese Toddlers
Brief Summary: This study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in the primary study. The study will also assess the immunogenicity and reactogenicity of a booster dose of IPV in subjects primed with three doses of IPV.


Options:
A: Arm Label: IPV/IPV/IPV/Rotarix/mOPV type 2; Type: EXPERIMENTAL; Interventions: Biological: IPV, Biological: mOPV type 2, Biological: Rotarix | Arm Label: IPV/IPV/bOPV/Rotarix/mOPV type 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: IPV, Biological: bOPV, Biological: mOPV type 2, Biological: Rotarix | Arm Label: IPV/bOPV/bOPV/Rotarix/mOPV type 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: IPV, Biological: bOPV, Biological: mOPV type 2, Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: IPV; Assigned to Arm(s): IPV/IPV/IPV/Rotarix/mOPV type 2, IPV/IPV/bOPV/Rotarix/mOPV type 2, IPV/bOPV/bOPV/Rotarix/mOPV type 2 | Intervention Type: BIOLOGICAL; Name: bOPV; Assigned to Arm(s): IPV/IPV/bOPV/Rotarix/mOPV type 2, IPV/bOPV/bOPV/Rotarix/mOPV type 2 | Intervention Type: BIOLOGICAL; Name: mOPV type 2; Assigned to Arm(s): IPV/IPV/IPV/Rotarix/mOPV type 2, IPV/IPV/bOPV/Rotarix/mOPV type 2, IPV/bOPV/bOPV/Rotarix/mOPV type 2 | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): IPV/IPV/IPV/Rotarix/mOPV type 2, IPV/IPV/bOPV/Rotarix/mOPV type 2, IPV/bOPV/bOPV/Rotarix/mOPV type 2
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Oral polio vaccine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Oral polio vaccine; Assigned to Arm(s): A
C: Arm Label: IPV Group; Type: EXPERIMENTAL; Interventions: Biological: Poliorix | Intervention Type: BIOLOGICAL; Name: Poliorix; Assigned to Arm(s): IPV Group
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: PoliorixTM, Biological: Infanrix+Hib | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Infanrix+Hib | Intervention Type: BIOLOGICAL; Name: PoliorixTM; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Infanrix+Hib; Assigned to Arm(s): Group A, Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia
Brief Summary: This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients. The primary objective is to establish the efficacy of PA21 for lowering phosphate levels in these patients.


Options:
A: Arm Label: PA21 (2.5 g tablet); Type: EXPERIMENTAL; Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron) | Arm Label: Sevelamer carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Arm Label: PA21-1 (1.25 g tablet); Type: OTHER; Interventions: Drug: PA21-1 (1.25 g tablet containing 250 mg iron) | Intervention Type: DRUG; Name: PA21 (2.5 g tablet containing 500 mg iron); Assigned to Arm(s): PA21 (2.5 g tablet) | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): Sevelamer carbonate | Intervention Type: DRUG; Name: PA21-1 (1.25 g tablet containing 250 mg iron); Assigned to Arm(s): PA21-1 (1.25 g tablet)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: sevelamer phosphate-binders | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium Carbonate | Intervention Type: DRUG; Name: sevelamer phosphate-binders; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium Carbonate; Assigned to Arm(s): 2
D: Arm Label: 1 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Arm Label: 6 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Arm Label: 8 g/day; Type: EXPERIMENTAL; Interventions: Drug: ferric citrate | Intervention Type: DRUG; Name: ferric citrate; Assigned to Arm(s): 1 g/day, 6 g/day, 8 g/day

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI): Cluster-randomized Controlled Trial
Brief Summary: ST segment elevation myocardial infarction (STEMI) is a common presentation of heart attack constituting approximately 30% of all cases. Clinical guidelines around the world support the prolonged use of secondary preventative medications including aspirin, clopidogrel, statin, beta-blocker and angiotensin blockers with the highest recommendations. While in-hospital and discharge prescription rates are excellent, adherence to these essential life-saving medications is far less than ideal, even a few months following hospital discharge. The investigators plan to capitalize on the existing structure of the SMART-AMI project already underway in LHIN IV to undertake a randomized controlled trial evaluating a reminder sent on behalf of the interventional cardiologists, delivered by mail, at 1, 2, 5, 8, and 11-months post-discharge, reviewing the evidence for life-saving cardiac medications and urging long-term adherence to secondary preventative cardiac medications. This will be sent to the family physician and the patient, using audience-appropriate language. If the DERLA-STEMI project is accepted by physicians and patients, found to be both feasible and effective, then this simple and low-cost intervention will be studied in all patients with an abnormal coronary angiogram.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention
B: Arm Label: Shed-Meds: A Patient-Centered Deprescribing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Shed-Meds: A Patient-Centered Deprescribing Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shed-Meds: A Patient-Centered Deprescribing Intervention; Assigned to Arm(s): Shed-Meds: A Patient-Centered Deprescribing Intervention
C: Arm Label: Pharmacist management; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical pharmacist-based intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical pharmacist-based intervention; Assigned to Arm(s): Pharmacist management
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Literacy-Focused High Blood Pressure Intervention | Intervention Type: BEHAVIORAL; Name: Health Literacy-Focused High Blood Pressure Intervention; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI): Cluster-randomized Controlled Trial
Brief Summary: ST segment elevation myocardial infarction (STEMI) is a common presentation of heart attack constituting approximately 30% of all cases. Clinical guidelines around the world support the prolonged use of secondary preventative medications including aspirin, clopidogrel, statin, beta-blocker and angiotensin blockers with the highest recommendations. While in-hospital and discharge prescription rates are excellent, adherence to these essential life-saving medications is far less than ideal, even a few months following hospital discharge. The investigators plan to capitalize on the existing structure of the SMART-AMI project already underway in LHIN IV to undertake a randomized controlled trial evaluating a reminder sent on behalf of the interventional cardiologists, delivered by mail, at 1, 2, 5, 8, and 11-months post-discharge, reviewing the evidence for life-saving cardiac medications and urging long-term adherence to secondary preventative cardiac medications. This will be sent to the family physician and the patient, using audience-appropriate language. If the DERLA-STEMI project is accepted by physicians and patients, found to be both feasible and effective, then this simple and low-cost intervention will be studied in all patients with an abnormal coronary angiogram.


Options:
A: Arm Label: CARE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter Reminder and Evaluation Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Catheter Reminder and Evaluation Program; Assigned to Arm(s): CARE
B: Arm Label: Advice on DDIs; Type: EXPERIMENTAL; Interventions: Behavioral: Advice on DDIs | Arm Label: General advice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Advice on DDIs; Assigned to Arm(s): Advice on DDIs
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Early Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI): Cluster-randomized Controlled Trial
Brief Summary: ST segment elevation myocardial infarction (STEMI) is a common presentation of heart attack constituting approximately 30% of all cases. Clinical guidelines around the world support the prolonged use of secondary preventative medications including aspirin, clopidogrel, statin, beta-blocker and angiotensin blockers with the highest recommendations. While in-hospital and discharge prescription rates are excellent, adherence to these essential life-saving medications is far less than ideal, even a few months following hospital discharge. The investigators plan to capitalize on the existing structure of the SMART-AMI project already underway in LHIN IV to undertake a randomized controlled trial evaluating a reminder sent on behalf of the interventional cardiologists, delivered by mail, at 1, 2, 5, 8, and 11-months post-discharge, reviewing the evidence for life-saving cardiac medications and urging long-term adherence to secondary preventative cardiac medications. This will be sent to the family physician and the patient, using audience-appropriate language. If the DERLA-STEMI project is accepted by physicians and patients, found to be both feasible and effective, then this simple and low-cost intervention will be studied in all patients with an abnormal coronary angiogram.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention
B: Arm Label: Learning and coping arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Learning and coping arm | Arm Label: Control arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Control arm | Intervention Type: BEHAVIORAL; Name: Learning and coping arm; Assigned to Arm(s): Learning and coping arm | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control arm
C: Arm Label: Stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation | Arm Label: health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): health education
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Group | Intervention Type: BEHAVIORAL; Name: Intervention Group; Assigned to Arm(s): Intervention Group

Answer: A